Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5)
•••
Hydro1
X
View Profile
View Bullboard History
Comment by
Hydro1
on Nov 21, 2024 10:56pm
RE:new article
Try this link: :''https://healthandpharma.net/oncolife/5''. It is on page 26 to 29.
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 21, 2024 8:03pm
RE:RE:RE:RE:My thanks , philosophical thoughts
Using an adaptive model of trial design, starting a Phase 2 trial and then getting an Accelerated Approval has the Phase 2 trial transformed into a Phase 3 / Phase 4 post approval confirmatory trial
...more
(114)
•••
spesestsemper
X
View Profile
View Bullboard History
Post by
spesestsemper
on Nov 21, 2024 6:01pm
new article
How Oncolytic Viruses Could Be a New Frontier in Transforming Cancer Treatment
(95)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Nov 21, 2024 5:43pm
RE:RE:RE:My thanks , philosophical thoughts
well, yes, accelerated approval would be excellent... pray tell how that can happen without data ?? the HAVE to run another Phase II first... one that has been statistically powered to confirm
...more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 21, 2024 11:03am
RE:RE:How does Accelerated Approval work
Phase 2 Ziihera is approved under the FDA’s accelerated pathway. To keep it on the market, Jazz and Zymeworks are running the Phase III HERIZON-BTC-302 confirmatory trial, which is assessing Ziihera
...more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 21, 2024 11:00am
RE:How does Accelerated Approval work
November 21, 2024 - Vancouver BC. - FDA grants Zymeworks Inc its.Phase 2 HER2+ bispecifc antibody zanidatamab (Ziihera) Accelerated Approval for the treatment of unresectable or
...more
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 20, 2024 9:39pm
RE:RE:Pfizer appoints chief oncology officer as new CSO
Chris Boshoff is personally familiar working with ONCY and has Pfizer has developed the SC delivered PD-1 checkpoint inhibitor sasanlimab that can benefit from the addition of ONCY's IV delivered&
...more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 20, 2024 9:13pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Whoever acquires pelareorep will brand the drug with a new trade name for commercialization, and the brand name Reolysin is no longer relevant.
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 20, 2024 9:09pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
The expired patents have established prior art and there was no good reason to have extended them. Meanwhile the composition of matter is extendable to 2031 and the new patents will further protect
...more
(217)
•••
inthno
X
View Profile
View Bullboard History
Comment by
inthno
on Nov 20, 2024 8:25pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Hello and curious as to why the patents have not been extended rather than repeating that they can be extended. Would it not be easier to just extend them now and remove all doubt such as maybe
...more
(193)
•••
settoretire
X
View Profile
View Bullboard History
Comment by
settoretire
on Nov 20, 2024 7:42pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
No, you're mistaken. What I mean is, one set of governance is for the people, by the people. The other is, do as I say, not as I do. There is a definite distinction between the two.
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 20, 2024 5:29pm
RE:ONCY new patent published effective October 24, 2024
Title: LIQUID VIRAL FORMULATIONS Issued on 2023-04-25 Effective until : 2031-12-02
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Nov 20, 2024 5:10pm
ONCY new patent published effective October 24, 2024
Title : IMPROVEMENT IN VIRAL EXTRACTION FROM CELL CULTURE
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 20, 2024 3:57pm
RE:RE:RE:My thanks , philosophical thoughts
Oncy accelerated approval... lmfao
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 20, 2024 3:49pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Should read: ONCY's original composition of matter patent on pelareorep can be extended until 2031, while ONCY's modified non-reovirus (pelareorep) virus comprising a reovirus sigma-1 protein
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden